Responses
Extended report
Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy
Compose a Response to This Article
Other responses
No responses have been published for this article.